Author

M. N. Paddock

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell signaling & trafficking· 3 Approach:experimental assay· 3 Organism:human· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

L. C. Cantley· 3 shared B. D. Hopkins· 2 shared D. G. Wang· 2 shared M. R. Lundquist· 2 shared T. J. Yang· 2 shared A. Hill· 1 shared B. Jiang· 1 shared C. Hodakoski· 1 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPhysiology

L. C. Cantley

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Epinephrine inhibits PI3K alpha via the Hippo kinases.

T.-Y. Lin, S. Ramsamooj, K. Liberatore, L. Lantier, N. Vasan, K. Karukurichi, S.-K. Hwang, E. A. Kesicki, E. R. Kastenhuber, T. Wiederhold, T. M. Yaron, M. Zhu, Y. Ma, M. N. Paddock, G. Zhang, , M. D. Goncalves

The paper identifies Hippo kinases as inhibitors of PI3K alpha, showing epinephrine activates these kinases to suppress insulin signaling and glucose metabolism.

bioRxiv · Jul 19, 2022 · PreprintPhysiology

Targeting the PI5P4K lipid kinase family in cancer using novel covalent inhibitors

S. C. Sivakumaren, H. Shim, T. Zhang, F. M. Ferguson, M. R. Lundquist, C. M. Browne, H.-S. Seo, M. N. Paddock, T. D. Manz, B. Jiang, M.-F. Hao, P. Krishnan, D. G. Wang, T. J. Yang, N. P. Kwiatkowski, , N. S. Gray

This study identifies THZ-P1-2, a covalent pan-PI5P4K inhibitor, showing efficacy in AML/ALL cell lines and autophagy disruption, supporting PI5P4Ks as therapeutic targets in cancer.

bioRxiv · Oct 25, 2019Cancer Biology

PIP4Ks Suppress Insulin Signaling Through a Catalytic-Independent Mechanism

D. G. Wang, M. N. Paddock, M. R. Lundquist, J. Y. Sun, O. Mashadova, S. Amadiume, T. W. Bumpus, C. Hodakoski, B. D. Hopkins, M. Fine, A. Hill, T. J. Yang, J. M. Baskin, L. E. Dow, L. C. Cantley

This study shows that PIP4Ks suppress insulin signaling through a non-catalytic mechanism by regulating PIP5K activity and PI(4,5)P2 levels.

bioRxiv · Jul 20, 2018Cell Biology